English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Gliomas are neoplasm of the central nervous system and make up approximately 80% of all malignant brain tumors. Even with the advancement in the field of surgery, chemotherapy and radiotherapy, the prognosis of glioma patients is dismal. Many molecular alterations of various oncogenes and tumor suppressor genes are seen in glioma and can be used for molecular characterization of tumor. The Bmi1 is a Polycomb group of protein which is associated with various cancers. The main alterations in Bmi1 gene in glioma includes copy number variation, over expression of mRNA and protein levels when compared to the non glioma brain samples. The CDKN2A (p16) is a tumor suppressor gene, mapped to 9p21. Alterations of the 9p21 locus have been implicated in many types of cancer, indicating the role of the tumor suppressor genes CDKN2A which encodes for p16/p14. In this study we wanted to check the gene expression pattern of p16 and Bmi1 genes in glioma and their clinical correlations.

Correlation o P16 and Bmi1 gene expression in human high grade glioma